{"id":40312,"date":"2023-03-20T15:42:42","date_gmt":"2023-03-20T07:42:42","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=40312"},"modified":"2023-03-28T11:38:01","modified_gmt":"2023-03-28T03:38:01","slug":"%e7%a3%b7%e9%85%b8%e5%8c%96-akt-ser473%e6%8a%97%e9%ab%94-phospho-akt-ser473-antibody%e8%b2%a8%e8%99%9fir172-668-ireal-biotechnology-%e8%89%be%e9%8b%ad%e7%94%9f%e6%8a%80","status":"publish","type":"post","link":"http:\/\/biopioneer.com.tw\/?p=40312","title":{"rendered":"\u78f7\u9178\u5316 AKT (Ser473)\u6297\u9ad4 |Phospho-AKT (Ser473) antibody\u8ca8\u865fIR172-668 (IReal Biotechnology \u827e\u92ed\u751f\u6280)"},"content":{"rendered":"

\"HOT\"<\/a>\u78f7\u9178\u5316 AKT (Ser473)\u6297\u9ad4 |Phospho-AKT (Ser473) antibody\u8ca8\u865fIR172-668 (IReal Biotechnology \u827e\u92ed\u751f\u6280)<\/a><\/span><\/strong><\/span><\/p>\n

Phospho-AKT (Ser473) antibody (IReal Biotechnology \u827e\u92ed\u751f\u6280,IR172-668)<\/p>\n

iReal \u827e\u92b3\u751f\u6280\u7368\u5bb6\u6253\u9020\u51faMonoclonal-like Polyclonal Antibody\uff0c\u514d\u75ab\u539f(Immunogen)\u70ba\u61c9\u7528\u77ed\u93c8\u80dc\u80bd(peptide)\u70ba\u6297\u539f\u8a2d\u8a08\u51fa\u767c\u9ede\uff0c\u6311\u9078\u5404\u86cb\u767d\u6700\u4f73\u7684\u4f4d\u9ede(epitope) \u8fa8\u8b58\u4f4d\u4f86\u8fa8\u8a8d\u76ee\u6a19\u86cb\u767d\uff0ciReal\u00a0\u514d\u75ab\u8840\u6e05\u7d93\u904e\u4e00\u9023\u591a\u6b65\u9a5f\u7684\u7d14\u5316\u904e\u7a0b(Affinity column purified )\uff0c\u53bb\u9664\u6389\u5404\u7a2e\u975e\u5c08\u4e00\u6027\u7684\u86cb\u767d\uff0c\u4ee5\u964d\u4f4e\u6297\u9ad4\u7684\u80cc\u666f\u503c\uff1b\u540c\u6642\u85c9\u7531\u5154\u5b50\u7368\u7279\u7684\u514d\u75ab\u7cfb\u7d71\u6240\u7522\u751f\u7684\u6297\u9ad4\uff0c\u80fd\u5920\u7522\u2f63\u8a31\u591a\u2f7c\u2fcf\u514d\u75ab\u7cfb\u7d71\u4e0d\u80fd\u8b58\u5225\u7684\u6297\u539f\u7684\u6297\u9ad4\u3002\u64c1\u6709\u5404\u5b78\u8853\u55ae\u4f4d\u771f\u5be6\u6578\u64da\u7684\u9a57\u8b49\uff0c\u4e26\u5177\u5099\u81e8\u5e8a\u9a57\u8b49\u898f\u683c\u7684\u6297\u9ad4\u54c1\u8cea\uff0c\u5927\u91cf\u4e14\u73fe\u8ca8\u4f9b\u61c9\u3002<\/p>\n

Phospho-AKT (Ser473) antibody\u00a0<\/span>(Endogenous)\uff0c\u91dd\u5c0dPhospho-AKT (Ser473)\u5177\u6709\u5c08\u4e00\u8868\u73fe\uff0c\u53ef\u61c9\u7528\u65bcWestern Blot\u3001IF\u5be6\u9a57\uff0c\u7269\u7a2e\u4f86\u6e90\u70baRabbit-IgG\uff0c\u53cd\u61c9\u7269\u7a2e: Human\u3001Mouse\u3001Rat\u3002<\/p>\n

Weatern Blot\u64cd\u4f5c\u624b\u518a<\/a><\/span><\/p>\n

Western Blot 1:500- 1:1000
\nImmunofluorescence 1:200-1:400<\/p>\n

\u78f7\u9178\u5316 AKT (Ser473)\u6297\u9ad4Vimentin antibody\u7522\u54c1\u4ecb\u7d39:<\/span><\/strong><\/span><\/p>\n

This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine\/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT\/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K\/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]<\/p>\n

\u8a72\u57fa\u56e0\u7de8\u78bc\u4eba\u985e AKT \u7d72\u6c28\u9178-\u8607\u6c28\u9178\u86cb\u767d\u6fc0\u9176\u5bb6\u65cf\u7684\u4e09\u500b\u6210\u54e1\u4e4b\u4e00\uff0c\u901a\u5e38\u7a31\u70ba\u86cb\u767d\u6fc0\u9176 B \u03b1\u3001\u03b2 \u548c\u03b3\u3002\u9019\u4e9b\u9ad8\u5ea6\u76f8\u4f3c\u7684 AKT \u86cb\u767d\u90fd\u6709\u4e00\u500b N \u7aef pleckstrin \u540c\u6e90\u7d50\u69cb\u57df\u3001\u4e00\u500b\u7d72\u6c28\u9178\/\u8607\u6c28\u9178\u7279\u7570\u6027\u6fc0\u9176\u7d50\u69cb\u57df\u548c\u4e00\u500b C \u7aef\u8abf\u7bc0\u7d50\u69cb\u57df\u3002\u9019\u4e9b\u86cb\u767d\u8cea\u88ab\u78f7\u9178\u808c\u9187 3-\u6fc0\u9176 (PI3K) \u78f7\u9178\u5316\u3002AKT\/PI3K \u662f\u8a31\u591a\u4fe1\u865f\u901a\u8def\u7684\u95dc\u9375\u7d44\u6210\u90e8\u5206\uff0c\u9019\u4e9b\u4fe1\u865f\u901a\u8def\u6d89\u53ca\u819c\u7d50\u5408\u914d\u9ad4\u7684\u7d50\u5408\uff0c\u4f8b\u5982\u53d7\u9ad4\u916a\u6c28\u9178\u6fc0\u9176\u3001G \u86cb\u767d\u5076\u806f\u53d7\u9ad4\u548c\u6574\u5408\u7d20\u9023\u63a5\u6fc0\u9176\u3002\u56e0\u6b64\uff0c\u9019\u4e9b AKT \u86cb\u767d\u8abf\u7bc0\u591a\u7a2e\u7d30\u80de\u529f\u80fd\uff0c\u5305\u62ec\u6b63\u5e38\u7d30\u80de\u548c\u60e1\u6027\u7d30\u80de\u4e2d\u7684\u7d30\u80de\u589e\u6b96\u3001\u5b58\u6d3b\u3001\u4ee3\u8b1d\u548c\u8840\u7ba1\u751f\u6210\u3002\u78f7\u8102\u9170\u808c\u9187 4,5-\u4e8c\u78f7\u9178 (PIP2) \u88ab PI3K \u78f7\u9178\u5316\u5f8c\uff0cAKT \u86cb\u767d\u88ab\u78f7\u8102\u9170\u808c\u9187 3,4,5-\u4e09\u78f7\u9178 (PIP3) \u52df\u96c6\u5230\u7d30\u80de\u819c\u4e0a\u3002\u8607\u6c28\u9178\u6b98\u57fa 308 \u548c\u7d72\u6c28\u9178\u6b98\u57fa 473 \u7684\u5f8c\u7e8c\u78f7\u9178\u5316\u662f\u5b8c\u5168\u6fc0\u6d3b\u8a72\u57fa\u56e0\u7de8\u78bc\u7684 AKT1 \u86cb\u767d\u6240\u5fc5\u9700\u7684\u3002\u5176\u4ed6\u6b98\u57fa\u7684\u78f7\u9178\u5316\u4e5f\u6703\u767c\u751f\uff0c\u4f8b\u5982\uff0c\u97ff\u61c9\u80f0\u5cf6\u7d20\u751f\u9577\u56e0\u5b50-1 \u548c\u8868\u76ae\u751f\u9577\u56e0\u5b50\u3002\u86cb\u767d\u78f7\u9178\u9176\u901a\u904e\u4f7f AKT \u6216 PIP3 \u53bb\u78f7\u9178\u5316\u800c\u5145\u7576 AKT \u86cb\u767d\u7684\u8ca0\u8abf\u7bc0\u5291\u3002PI3K\/AKT \u4fe1\u865f\u901a\u8def\u5c0d\u816b\u7624\u7d30\u80de\u5b58\u6d3b\u81f3\u95dc\u91cd\u8981\u3002\u5b58\u6d3b\u56e0\u5b50\u53ef\u4ee5\u901a\u904e\u6fc0\u6d3b AKT1 \u4ee5\u8f49\u9304\u975e\u4f9d\u8cf4\u6027\u65b9\u5f0f\u6291\u5236\u7d30\u80de\u51cb\u4ea1\uff0c\u7136\u5f8c\u78f7\u9178\u5316\u548c\u6ec5\u6d3b\u7d30\u80de\u51cb\u4ea1\u6a5f\u5236\u7684\u7d44\u5206\u3002AKT \u86cb\u767d\u9084\u53c3\u8207\u54fa\u4e73\u52d5\u7269\u96f7\u5e15\u9ef4\u7d20\u9776\u6a19 (mTOR) \u4fe1\u865f\u901a\u8def\uff0c\u8a72\u901a\u8def\u63a7\u5236\u771f\u6838\u7ffb\u8b6f\u8d77\u59cb\u56e0\u5b50 4F (eIF4E) \u8907\u5408\u7269\u7684\u7d44\u88dd\uff0c\u4e26\u4e14\u9664\u4e86\u97ff\u61c9\u4f86\u81ea\u751f\u9577\u56e0\u5b50\u548c\u7d30\u80de\u56e0\u5b50\u7684\u7d30\u80de\u5916\u4fe1\u865f\u5916\uff0c\u8a72\u901a\u8def\u5728\u8a31\u591a\u764c\u75c7\u3002\u8a72\u57fa\u56e0\u7684\u7a81\u8b8a\u8207\u591a\u7a2e\u985e\u578b\u7684\u764c\u75c7\u548c\u7d44\u7e54\u904e\u5ea6\u751f\u9577\u6709\u95dc\uff0c\u5305\u62ec\u8b8a\u5f62\u687f\u83cc\u7d9c\u5408\u5fb5\u548c\u8003\u767b\u7d9c\u5408\u5fb5 6\uff0c\u4ee5\u53ca\u4e73\u817a\u764c\u3001\u7d50\u76f4\u8178\u764c\u548c\u5375\u5de2\u764c\u3002\u5df2\u767c\u73fe\u8a72\u57fa\u56e0\u7684\u591a\u500b\u9078\u64c7\u6027\u526a\u63a5\u8f49\u9304\u7269\u8b8a\u9ad4\u3002[\u7531 RefSeq \u63d0\u4f9b\uff0c2020 \u5e74 7 \u6708]\u00a0\u9664\u4e86\u97ff\u61c9\u4f86\u81ea\u751f\u9577\u56e0\u5b50\u548c\u7d30\u80de\u56e0\u5b50\u7684\u7d30\u80de\u5916\u4fe1\u865f\u5916\uff0c\u5728\u8a31\u591a\u764c\u75c7\u4e2d\u5931\u8abf\u3002\u8a72\u57fa\u56e0\u7684\u7a81\u8b8a\u8207\u591a\u7a2e\u985e\u578b\u7684\u764c\u75c7\u548c\u7d44\u7e54\u904e\u5ea6\u751f\u9577\u6709\u95dc\uff0c\u5305\u62ec\u8b8a\u5f62\u687f\u83cc\u7d9c\u5408\u5fb5\u548c\u8003\u767b\u7d9c\u5408\u5fb5 6\uff0c\u4ee5\u53ca\u4e73\u817a\u764c\u3001\u7d50\u76f4\u8178\u764c\u548c\u5375\u5de2\u764c\u3002\u5df2\u767c\u73fe\u8a72\u57fa\u56e0\u7684\u591a\u500b\u9078\u64c7\u6027\u526a\u63a5\u8f49\u9304\u7269\u8b8a\u9ad4\u3002[\u7531 RefSeq \u63d0\u4f9b\uff0c2020 \u5e74 7 \u6708]\u00a0\u9664\u4e86\u97ff\u61c9\u4f86\u81ea\u751f\u9577\u56e0\u5b50\u548c\u7d30\u80de\u56e0\u5b50\u7684\u7d30\u80de\u5916\u4fe1\u865f\u5916\uff0c\u5728\u8a31\u591a\u764c\u75c7\u4e2d\u5931\u8abf\u3002\u8a72\u57fa\u56e0\u7684\u7a81\u8b8a\u8207\u591a\u7a2e\u985e\u578b\u7684\u764c\u75c7\u548c\u7d44\u7e54\u904e\u5ea6\u751f\u9577\u6709\u95dc\uff0c\u5305\u62ec\u8b8a\u5f62\u687f\u83cc\u7d9c\u5408\u5fb5\u548c\u8003\u767b\u7d9c\u5408\u5fb5 6\uff0c\u4ee5\u53ca\u4e73\u817a\u764c\u3001\u7d50\u76f4\u8178\u764c\u548c\u5375\u5de2\u764c\u3002\u5df2\u767c\u73fe\u8a72\u57fa\u56e0\u7684\u591a\u500b\u9078\u64c7\u6027\u526a\u63a5\u8f49\u9304\u7269\u8b8a\u9ad4\u3002[\u7531 RefSeq \u63d0\u4f9b\uff0c2020 \u5e74 7 \u6708]<\/p>\n

\"\"<\/p>\n

\"\u7db2\u7ad9\u898f\u683c\u5c0f\u5716_\u5de5\u4f5c\u5340\u57df<\/a><\/p>\n

\"IR1-2\u6297\u03b2\u5fae\u7ba1\u86cb\u767d\u6297\u9ad4WB\u5716\u50cf\"<\/p>\n

\u6297 AKT\uff08\u6cdb\uff09\u6297\u9ad4 WB \u5716\u50cf(IREAL, #IR172-668)<\/span><\/strong><\/span>
\n\u6240\u6709\u6cf3\u9053\uff1a1\/500 \u7a00\u91cb\u7684\u6297 AKT\uff08\u6cdb\uff09\u6297\u9ad4
\n\u88c2\u89e3\u7269\/\u86cb\u767d\u8cea\uff0c\u6bcf\u6cf3\u9053 60 \u03bcg
\n\u8a72\u5370\u8de1\u662f\u4f7f\u7528 7.5% SDS-PAGE \u7522\u751f\u7684\u3002\u51dd\u81a0\u5728 140V \u4e0b\u904b\u884c 50 \u5206\u9418\uff0c\u7136\u5f8c\u5728 18V \u4e0b\u8f49\u79fb\u5230\u785d\u9178\u7e96\u7dad\u7d20\u819c\u4e0a 60 \u5206\u9418\u3002\u7136\u5f8c\u5c07\u819c\u5c01\u9589 1 \u5c0f\u6642\uff0c\u7136\u5f8c\u8207 IR172-668 \u5728 4\u00b0C \u4e0b\u5b75\u80b2\u904e\u591c\u3002<\/p>\n\n\n\n\n\n\n\n
IR300-981<\/td>\nCD9<\/a><\/span><\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IF, IHC<\/td>\n<\/tr>\n
IR301-983<\/td>\nCD63<\/a><\/span><\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IHC, FC<\/td>\n<\/tr>\n
IR302-986<\/td>\nCD81<\/a><\/span><\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IF, IHC<\/td>\n<\/tr>\n
IR304-990<\/td>\nFlotillin-1<\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IF, IHC<\/td>\n<\/tr>\n
IR303-988<\/td>\nALIX\u6297\u9ad4<\/a><\/span><\/td>\nExosome Biomarker<\/td>\nRabbit<\/td>\nH,M,R<\/td>\nWB, IF, IHC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/p>\n

IHC\/\u75c5\u7406\u5b78\u6297\u9ad4(IHC\/Pathology antibodies)<\/span><\/strong><\/span><\/p>\n

Please note that related Positive Control Slides are also available. \u5206\u5b50\u75c5\u7406\u5b78(molecular pathology)\u4e2d\u7684\u514d\u75ab\u7d44\u7e54\u5316\u5b78(Immunohistochemistry)\u626e\u6f14\u91cd\u8981\u4f5c\u7528\uff1a\u8a3a\u65b7(Diagnosis)\u3001\u9810\u5f8c(Prognosis)\u548c\u9810\u6e2c(Predictive)\u3002 IHC \u6297\u9ad4(IHC antibodies)\u5df2\u88ab\u78ba\u5b9a\u70ba\u7528\u65bc\u798f\u723e\u99ac\u6797\u56fa\u5b9a\u77f3\u881f\u5207\u7247(formalin-fixed paraffin sections)\u514d\u75ab\u7d44\u7e54\u5316\u5b78(immunohistochemistry)\u7684\u6700\u4f73\u8a66\u5291\u3002\u6240\u6709 IHC\/\u75c5\u7406\u5b78\u6297\u9ad4(IHC\/Pathology antibodies)\u50c5\u4f9b\u7814\u7a76\u4f7f\u7528\u3002IHC\/\u75c5\u7406\u5b78\u6297\u9ad4\u5df2\u7d93\u91dd\u5c0d\u4eba\u9ad4\/\u8001\u9f20\/\u5927\u9f20\u7d44\u7e54\u7684\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u9032\u884c\u4e86\u5ee3\u6cdb\u7684\u6e2c\u8a66\u548c\u9a57\u8b49(Pathology validated)\uff0c\u4e26\u7d93\u904e\u7cbe\u5fc3\u8a2d\u8a08\uff0c\u53ef\u63d0\u4f9b\u4e00\u81f4\u3001\u7279\u7570\u6027\u548c\u654f\u611f\u7684\u67d3\u8272\u3002<\/p>\n

PD-1\u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>\u7a0b\u5e8f\u6027\u6b7b\u4ea1 1 (Programmed Death 1, PD-1) \u662f T \u7d30\u80de\u8abf\u7bc0\u5291(T-cell regulators) CD28\/CTLA-4 \u5bb6\u65cf\u7684\u6210\u54e1\uff0c\u5728\u6d3b\u5316\u7684 T \u7d30\u80de\u3001B \u7d30\u80de\u548c\u5de8\u566c\u7d30\u80de\u8868\u9762\u8868\u9054\u70ba\u5171\u53d7\u9ad4(co-receptor)\u3002\u65b0\u7684\u7814\u7a76\u8868\u660e\uff0cPD-1\/PD-L1 \u4fe1\u865f\u901a\u8def\u53ef\u80fd\u8207\u6297\u816b\u7624\u514d\u75ab\u6709\u95dc\uff0c\u56e0\u70ba PD-L1 \u5df2\u88ab\u8b49\u660e\u53ef\u8a98\u5c0e\u6d3b\u5316 T \u7d30\u80de\u51cb\u4ea1(apoptosis)\u6216\u6291\u5236\u7d30\u80de\u6bd2\u6027 T \u7d30\u80de(cytotoxic T cells)\u7684\u6d3b\u6027\u3002\u8207 CD10 \u548c BCL6 \u4e0d\u540c\uff0cPD-1 \u50c5\u7531\u5c11\u6578 B \u7d30\u80de\u8868\u9054\uff0c\u56e0\u6b64\u6297 PD-1 \u53ef\u80fd\u662f\u8840\u7ba1\u514d\u75ab\u6bcd\u7d30\u80de\u6027\u6dcb\u5df4\u7624(angioimmunoblastic lymphoma)\u4e2d\u66f4\u7279\u7570\u548c\u6709\u7528\u7684\u8a3a\u65b7\u6a19\u8a8c\u7269\u3002>>\u00a0PD-L1\/CD274 C\u672b\u7aef\u6297\u9ad4<\/a><\/span><\/p>\n

CTLA4\u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>CD152 \u6297\u539f\uff0c\u4e5f\u7a31\u70ba CTLA4\uff0c\u662f\u4e00\u7a2e\u5c6c\u65bc\u514d\u75ab\u7403\u86cb\u767d\u8d85\u5bb6\u65cf(immunoglobulin superfamily)\u7684\u5b8c\u6574\u819c\u86cb\u767d\uff0c\u5176\u8868\u9054\u70ba 30 kDa \u55ae\u9ad4(30 kDa monomer)\u6216\u4e8c\u786b\u9375\u9023\u63a5\u7684\u540c\u578b\u4e8c\u805a\u9ad4(disulfide-linked homodimer)\u3002\u5b83\u8207T\u7d30\u80de\u6297\u539fCD28(T cell antigen CD28)\u5177\u6709\u540c\u6e90\u6027\uff0c\u8207CD28\u4e00\u6a23\uff0c\u662fCD80\u548cCD86\u7684\u914d\u9ad4(ligand)\u3002 CTLA-4 \u662f T \u8f14\u52a9\u7d30\u80de\u4e0a\u7684\u4e00\u7a2e\u53d7\u9ad4\uff0c\u53ef\u4f5c\u70ba\u514d\u75ab\u6aa2\u67e5\u9ede(immune checkpoint)\u548c\u514d\u75ab\u53cd\u61c9\u7684\u4e0b\u8abf\u56e0\u5b50\u3002 CTLA-4 \u7684\u7a81\u8b8a\u8207\u8a31\u591a\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5(autoimmune diseases)\u6709\u95dc\u3002<\/p>\n

Lp-PLA2\u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>Lp-PLA2\uff0c\u4e5f\u7a31\u70ba\u8102\u86cb\u767d\u76f8\u95dc\u78f7\u8102\u9176 A2 (Lipoprotein-associated Phospholipase A2)\u6216\u8840\u5c0f\u677f\u6d3b\u5316\u56e0\u5b50\u4e59\u9170\u6c34\u89e3\u9176 (platelet-activating factor acetylhydrolase , PAF-AH)\uff0c\u662f\u4e00\u7a2e\u7531\u708e\u75c7\u7d30\u80de(inflammatory cells )\u7522\u751f\u7684\u9176\uff0c\u5176\u529f\u80fd\u662f\u4f7f\u8840\u5c0f\u677f\u6d3b\u5316\u56e0\u5b50(platelet-activating factor)\u5931\u6d3b\u548c\u964d\u89e3(degrade)\uff0c\u8840\u5c0f\u677f\u6d3b\u5316\u56e0\u5b50\u662f\u4e00\u7a2e\u6709\u6548\u7684\u4fc3\u708e\u6027\u78f7\u8102(pro-inflammatory phospholipid)\uff0c\u540c\u6642\u9084\u8ca0\u8cac\u6c34\u89e3\u6c27\u5316\u4fee\u98fe(hydrolyzing oxidatively modified)\u7684\u591a\u4e0d\u98fd\u548c\u8102\u80aa\u9178(polyunsaturated fatty acids)\u3002 Lp-PLA2 \u7684\u9176\u4fc3\u4f5c\u7528\u7522\u7269\u8207\u52d5\u8108\u7ca5\u6a23\u786c\u5316(atherosclerosis)\u7684\u767c\u5c55\u6709\u95dc\uff0c\u4e26\u8207\u51a0\u5fc3\u75c5(coronary heart disease)\u548c\u4e2d\u98a8(stroke)\u7684\u98a8\u96aa\u589e\u52a0\u5448\u6b63\u76f8\u95dc\u3002<\/p>\n

Muc2\u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>\u7c98\u86cb\u767d 2(Mucin 2)\uff0c\u4e5f\u7a31\u70ba MUC2\uff0c\u662f\u4e00\u7a2e\u7de8\u78bc\u7c98\u86cb\u767d\u5bb6\u65cf(mucin protein family)\u6210\u54e1\u7684\u4eba\u985e\u57fa\u56e0\u3002\u7531\u8a72\u57fa\u56e0\u7de8\u78bc\u7684\u86cb\u767d\u8cea\u5f62\u6210\u4fdd\u8b77\u8178\u8154(gut lumen)\u7684\u4e0d\u6eb6\u6027\u7c98\u6db2\u5c4f\u969c\u3002\u5728\u6b63\u5e38\u7d50\u8178(normal colon)\u3001\u4e73\u817a(breast)\u3001\u524d\u5217\u817a(prostate)\u548c\u553e\u6db2\u817a(salivary gland)\u7b49\u4eba\u9ad4\u7d44\u7e54\u4ee5\u53ca\u80c3\u8178\u9053(gastrointestinal)\u3001\u7d50\u8178(colonic)\u3001\u4e73\u817a(breast)\u548c\u524d\u5217\u817a\u816b\u7624(prostate neoplasia)\u4e2d\u6aa2\u6e2c\u5230 MUC2 \u8868\u9054\u3002<\/p>\n

\u7d30\u80de\u89d2\u86cb\u767d 18 (Cytokeratin 18) \u75c5\u7406\u5b78\u6297\u9ad4\uff1a<\/span>\u7d30\u80de\u89d2\u86cb\u767d 18 (Cytokeratin 18, CK 18) \u662f\u4e00\u7a2e 45kDa \u7684\u86cb\u767d\u8cea\uff0c\u5c6c\u65bc\u9178\u6027\u985e\u578b\u7684\u7d30\u80de\u89d2\u86cb\u767d(cytokeratins)\uff0c\u901a\u5e38\u5728\u7c21\u55ae\u7684\u975e\u5206\u5c64\u4e0a\u76ae\u7d30\u80de(non-stratified epithelia)\u4e2d\u8868\u9054\u3002\u7136\u800c\uff0cCK 18 \u4e5f\u5728\u79fb\u884c\u4e0a\u76ae(transitional epithelium)\u7684\u57fa\u5e95\u7d30\u80de\u548c\u8868\u5c64\u7d30\u80de\u4ee5\u53ca\u8907\u96dc\u4e0a\u76ae(complex epithelia)\u7684\u7ba1\u8154\/\u5206\u6ccc\u7d30\u80de(luminal\/secretory cells)\u4e2d\u8868\u9054\u3002 CK 18 \u6297\u9ad4\u5728\u8d77\u6e90\u65bc\u7c21\u55ae\u548c\u817a\u9ad4\u4e0a\u76ae(glandular epithelium)\u7684\u817a\u764c(Adenocarcinomas)\u4ee5\u53ca\u9c57\u72c0\u7d30\u80de\u764c(Squamous Carcinoma)\u7684\u4f4e\u5206\u5316\u816b\u7624\u7d30\u80de\u4e2d\u5448\u967d\u6027\u67d3\u8272\u3002<\/p>\n

MLH1\u75c5\u7406\u5b78\u6297\u9ad4\u00a0<\/span>\u662f\u4e00\u7a2e\u932f\u914d\u4fee\u5fa9\u86cb\u767d(mismatch repair protein)\uff0c\u8207 MSH2\u3001MSH6 \u548c PMS2 \u4e00\u8d77\u53c3\u8207\u7dad\u6301\u907a\u50b3\u4fe1\u606f\u7684\u5b8c\u6574\u6027\u3002\u9019\u7a2e\u86cb\u767d\u8cea\u901a\u5e38\u8207\u907a\u50b3\u6027(hereditary)\u975e\u606f\u8089\u75c5\u6027\u7d50\u76f4\u8178\u764c(non-polyposis colorectal cancer)\u6709\u95dc\uff0c\u56e0\u70ba MLH1 \u57fa\u56e0\u5728\u60a3\u6709\u9019\u7a2e\u764c\u75c7\u7684\u60a3\u8005\u4e2d\u7d93\u5e38\u767c\u751f\u7a81\u8b8a\u3002\u7814\u7a76\u8868\u660e\uff0cMLH1 \u5728\u5927\u90e8\u5206\u5fae\u885b\u661f\u4e0d\u7a69\u5b9a\u6027(microsatellite instability)\u4ee5\u53ca\u5b50\u5bae\u5167\u819c\u764c(endometrial)\u548c\u5375\u5de2\u764c(ovarian cancers)\u60a3\u8005\u4e2d\u5b58\u5728\u7f3a\u9677\u3002\u7576\u5728 IHC \u9762\u677f\u4e2d\u8207 MSH6\u3001MSH2 \u548c PMS2 \u914d\u5c0d\u6642\uff0c\u6297 MLH1 \u7684\u4f7f\u7528\u5f97\u5230\u512a\u5316\u3002<\/p>\n

HER2\u75c5\u7406\u5b78\u6297\u9ad4:<\/span><\/p>\n

HER2\u5728 10-20% \u7684\u4e73\u817a\u764c\u60a3\u8005(breast cancer patients)\u4e2d\u88ab\u8b58\u5225\u51fa\u4f86\u3002 Her2\/Neu (c-erbB-2) \u539f\u764c\u57fa\u56e0(proto-oncogene)\u662f\u4e00\u7a2e\u8de8\u819c\u53d7\u9ad4\u916a\u6c28\u9178\u6fc0\u9176(transmembrane receptor tyrosine kinase)\uff0c\u5728\u8a31\u591a\u764c\u75c7\u4e2d\u90fd\u6709\u81e8\u5e8a\u8868\u73fe\u3002 c-erbB-2 \u86cb\u767d\u7684\u904e\u5ea6\u8868\u9054(Overexpression)\u8207\u5c0e\u7ba1\u4e73\u817a\u764c(ductal breast cancer)\u4ee5\u53ca\u80ba\u817a\u764c(pulmonary)\u548c\u80c3\u817a\u764c(gastric adenocarcinomas)\u6709\u95dc\u3002Her2 \u548c p53 \u4e4b\u9593\u7684\u76f8\u95dc\u6027\u4e5f\u5df2\u88ab\u8b49\u660e\uff0c\u56e0\u70ba\u9019\u5169\u7a2e\u86cb\u767d\u7684\u904e\u5ea6\u8868\u9054\u8207\u8180\u80f1\u764c\u65e9\u671f\u4fb5\u8972(early invasion)\u548c\u8f49\u79fb(metastasis)\u6709\u95dc\u3002<\/p>\n

Ki-67\u00a0<\/span>\u662f\u4e00\u7a2e\u6838\u975e\u7d44\u86cb\u767d(nuclear non-histone protein)\uff0c\u5728\u975c\u6b62\u7d30\u80de(quiescent cells)\u4e2d\u4ee5\u4f4e\u6c34\u5e73\u5b58\u5728\uff0c\u4f46\u5728\u589e\u6b96\u7d30\u80de(proliferating cells)\u4e2d\u589e\u52a0\uff0c\u5c24\u5176\u662f\u5728 G2\u3001M \u548c S \u671f\u5f8c\u534a\u671f\u3002\u56e0\u6b64\uff0cKi-67 \u53cd\u61c9\u6027\uff08\u5b9a\u7fa9\u70ba\u901a\u904e IHC \u67d3\u8272\u6e2c\u91cf\u7684\u67d3\u8272\u967d\u6027\u7684\u816b\u7624\u7d30\u80de\u767e\u5206\u6bd4\uff09\u662f\u7d30\u80de\u589e\u6b96(cell proliferation)\u7684\u7279\u7570\u6027\u6838\u6a19\u8a18(nuclear marker )\u3002\u904e\u5ea6\u8868\u9054\u7d93\u5e38\u51fa\u73fe\u5728\u5404\u7a2e\u60e1\u6027\u7d44\u7e54(malignant tissues )\u4e2d\uff0c\u4e26\u4e14\u8207\u60a3\u6709\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624(neuroendocrine tumor)\u7684\u500b\u9ad4\u7684\u8f03\u5dee\u5b58\u6d3b\u7387\u76f8\u95dc\u3002>>IHC\u75c5\u7406\u5b78\u6297\u9ad4-Ki-67\u00a0\u6297\u9ad4<\/a>\u00a0<\/span><\/strong><\/span><\/p>\n

\"Better<\/p>\n

Exosome \u7814\u7a76\u5de5\u5177\/\u764c\u75c7\u76f8\u95dcExosomal Protein Marker<\/strong><\/span>–IReal Biotechnology<\/span><\/span><\/p>\n

IREAL\u63d0\u4f9b\u591a\u7a2e\u9ad8\u8cea\u91cf\u5916\u6ccc\u9ad4(exosomes)\u55ae\u591a\u682a\u6297\u9ad4 (IREAL Antibody)\uff0c\u5305\u62ecCD9(#IR300-981)<\/a><\/span>\u3001CD63(#IR301-983)<\/a><\/span>\u3001CD81(#IR302-986)<\/a><\/span>\u3001Flotillin-1(#IR304-990)<\/a>\u3001Alix(#IR303-988)<\/a><\/span>\u7b2c\u4e09\u65b9\u9a57\u8b49IHC\/IF\/WB\u6297\u9ad4\u3002\u5916\u6ccc\u9ad4(exosomes)\u53e6\u6709\u63d0\u4f9b\u5957\u7d44\u578b\u5f0f\u7684\u6297\u9ad4Panel\u5957\u7d44<\/a>\u3002<\/span><\/p>\n

\u8b58\u5225\u5916\u6ccc\u9ad4(exosomes)\u7684\u6700\u5e38\u898b\u8de8\u819c\u6a19\u8a18\u4f86\u81ea\u56db\u8de8\u819c\u86cb\u767d\u5bb6\u65cf\uff08CD63 \u3001CD81 \u548c CD9\uff09\u3002\u8a72\u5bb6\u65cf\u4e2d\u7684\u86cb\u767d\u8cea\u5177\u6709\u56db\u500b\u8de8\u819c\u5340\u57df\uff0c\u4e26\u4e14\u5b9a\u4f4d\u65bc\u8cea\u819c\u4e2d\u5bcc\u542b\u56db\u8de8\u819c\u86cb\u767d\u7684\u5fae\u57df (\u00a0tetraspanin enriched microdomains, TEM)\u3002\uff08CD63 \u3001CD81 \u3001 CD9\u53caCD82\uff09\u8207\u7c98\u9644\u5206\u5b50(\u00a0adhesion molecules)\u3001\u8de8\u819c\u53d7\u9ad4(\u00a0transmembrane receptors)\u548c\u7d30\u80de\u5167\u4fe1\u865f\u86cb\u767d(intracellular signaling proteins)\u76f8\u95dc\uff0c\u4ee5\u4fc3\u9032\u548c\u8abf\u7bc0\u4fe1\u865f(\u00a0signaling events)\u4e8b\u4ef6\u3002\u9ad8\u8cea\u91cf\u5916\u6ccc\u9ad4(exosomes)\u55ae\u591a\u682a\u6297\u9ad4 (IREAL Antibody)\uff0c\u63d0\u4f9b\u60a8\u66f4\u591aExosome \u7814\u7a76\u5de5\u5177\uff0c\u53ef\u61c9\u7528\u65bcIHC\/IF\/WB\u6297\u9ad4\u3002<\/p>\n

\"\u7db2\u7ad9\u898f\u683c\u5c0f\u5716<\/p>\n

BRAND\/AGENCY\/<\/strong>\u53f0\u7063\u4ee3\u7406\u5546<\/strong><\/span>\/<\/span>\u00a0<\/a><\/span><\/strong>IREAL<\/strong>\u827e\u92b3\u53f0\u7063\u4ee3\u7406\u5546<\/strong><\/a><\/span><\/span><\/p>\n

IREAL\u827e\u92ed\u5b98\u7db2\u00a0https:\/\/www.irealbio.com\/<\/a><\/span><\/p>\n

IREAL\u827e\u92ed\u751f\u7269\u79d1\u6280\u63d0\u4f9b\u6642\u4e0b\u71b1\u9580\u7814\u7a76\u9818\u57dfEMT marker\u3001Apoptosis\u3001ER stress\u3001Cell Cycle\u3001Autophagy\u53caNeuroscience\u7b49\u5e38\u7528\u6297\u9ad4\uff0c\u4e26\u63d0\u4f9b\u5ba2\u88fd\u5316\u6297\u9ad4\u670d\u52d9\u5e73\u53f0\u3002iReal\u00a0\u827e\u92ed\u751f\u7269\u79d1\u6280\u63d0\u4f9b\u6642\u4e0b\u71b1\u9580\u7814\u7a76\u9818\u57dfEMT marker\u3001Apoptosis\u3001ER stress\u3001Cell Cycle\u3001Autophagy\u53caNeuroscience\u7b49\u5e38\u7528\u6297\u9ad4\uff0c\u4e26\u63d0\u4f9b\u5ba2\u88fd\u5316\u6297\u9ad4\u670d\u52d9\u5e73\u53f0\u3002iReal \u827e\u92b3\u751f\u6280\u7368\u5bb6\u6253\u9020\u51faMonoclonal-like Polyclonal Antibody\uff0c\u514d\u75ab\u539f(Immunogen)\u70ba\u61c9\u7528\u77ed\u93c8\u80dc\u80bd(peptide)\u70ba\u6297\u539f\u8a2d\u8a08\u51fa\u767c\u9ede\uff0c\u6311\u9078\u5404\u86cb\u767d\u6700\u4f73\u7684\u4f4d\u9ede(epitope) \u8fa8\u8b58\u4f4d\u4f86\u8fa8\u8a8d\u76ee\u6a19\u86cb\u767d\uff0ciReal\u00a0\u514d\u75ab\u8840\u6e05\u7d93\u904e\u4e00\u9023\u591a\u6b65\u9a5f\u7684\u7d14\u5316\u904e\u7a0b(Affinity column purified )\uff0c\u53bb\u9664\u6389\u5404\u7a2e\u975e\u5c08\u4e00\u6027\u7684\u86cb\u767d\uff0c\u4ee5\u964d\u4f4e\u6297\u9ad4\u7684\u80cc\u666f\u503c\uff1b\u540c\u6642\u85c9\u7531\u5154\u5b50\u7368\u7279\u7684\u514d\u75ab\u7cfb\u7d71\u6240\u7522\u751f\u7684\u6297\u9ad4\uff0c\u80fd\u5920\u7522\u2f63\u8a31\u591a\u2f7c\u2fcf\u514d\u75ab\u7cfb\u7d71\u4e0d\u80fd\u8b58\u5225\u7684\u6297\u539f\u7684\u6297\u9ad4\u3002\u64c1\u6709\u5404\u5b78\u8853\u55ae\u4f4d\u771f\u5be6\u6578\u64da\u7684\u9a57\u8b49\uff0c\u4e26\u5177\u5099\u81e8\u5e8a\u9a57\u8b49\u898f\u683c\u7684\u6297\u9ad4\u54c1\u8cea\uff0c\u5927\u91cf\u4e14\u73fe\u8ca8\u4f9b\u61c9IHC\/IF\/WB\u6297\u9ad4\u3002<\/p>\n

\"IREAL\u827e\u92b3\u514d\u75ab\u67d3\u8272\u6297\u9ad4-\u592a\u9f0e\u751f\u6280_\u5de5\u4f5c\u5340\u57df<\/p>\n

\"\u578b\u9304\u4e0b\u8f09\"<\/p>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\u78f7\u9178\u5316 AKT (Ser473)\u6297\u9ad4 |Phospho-AKT (Ser473) antibody\u8ca8\u865fIR17 […]<\/p>\n","protected":false},"author":3,"featured_media":38534,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5264],"tags":[5416],"_links":{"self":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/40312"}],"collection":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40312"}],"version-history":[{"count":2,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/40312\/revisions"}],"predecessor-version":[{"id":40451,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/40312\/revisions\/40451"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/38534"}],"wp:attachment":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40312"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}